We also understand considerably more about synthesis and thereby reduce the number of GSL mol-
how the immune system responds to both endogenous ecules the cells degrade. These drugs have been evaluated
and exogenous lipids through the recent interest in the in multiple mouse models of GSL storage diseases, includ-
CD1 family of surface molecules. Glycolipids may in fact, ing those with brain involvement. In all cases efficacy has
provide tools to manipulate the immune system to inter- been demonstrated. Clinical trials in type 1 Gaucher
vene in certain disease states. disease have also demonstrated efficacy in man and
One of the major advances in recent years has been the recently the first drug in this class of compounds has been
manipulation of genes involved in glycolipid biosynthesis given a positive opinion recommending approval for its
and catabolism to probe basic glycosphingolipid (GSL) use in Europe.